Comparative evaluation of efficacy of terbinafine and itraconazole in treatment of tinea cruris
Keywords:Efficacy, Itraconazole, Terbinafine, Tinea Cruris
Background: In a hot and humid country like India, the prevalence of superficial mycotic infections is on the rise due to contributing environmental and demographic factors. In this study, we sought to assess the efficacies of two oral antifungal drugs, Itraconazole (a traditional azole) and Terbinafine (the only orally available allylamine). The two drugs were analyzed to see whether they differed significantly in their cure rates of tinea cruris. Since data, that compares only systemically administered Itraconazole and Terbinafine in the treatment of tinea cruris, is limited, this study becomes imperative.
Methods: 60 patients, all clinically confirmed cases of tinea cruris and belonging to the age group of 18-65 years, were recruited for this prospective study. Patients were then randomly divided into groups A and B and followed-up for a month. Group A received cap. Itraconazole 100 mg, twice a day, for 15 days while group B received tab. Terbinafine 250 mg, once a day, for 4 weeks. Both groups were given topical 2% Sertaconazole that had to be continued for 8 weeks. During the 4 visits, scores for the 3 parameters (erythema, pruritis and scaling) were calculated and recorded for statistical analysis.
Results: Authors observed that majority of the patients were exposed to hot and humid environment that contributed to sweating and poor personal hygiene. The changes in scores of erythema, pruritis and scaling from the baseline visit for both, Itraconazole and Terbinafine, were statistically significant at week 4 with P < 0.05 for all parameters. But the difference between the scores of the two drugs was not found to be statistically significant.Conclusions: Although the sample size of this study was small and the data was limited, findings of this study supported that both Itraconazole and Terbinafine were highly effective in the treatment of tinea cruris.
Pires CA, Cruz NF, Lobato AM, Sousa PO, Carneiro FR, Mendes AM. Clinical, epidemiological, and therapeutic profile of dermatophytosis. An Bras Dermatol. 2014;89(2):259-64.
Seebacher C, Bouchara JP, Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia. 2008;166(5-6):335.
Naglot A, Shrimali DD, Nath BK, Gogoi HK, Veer V, Chander J, et al. Recent Trends of Dermatophytosis in Northeast India (Assam) and Interpretation with Published Studies. Int J Curr Microbiol Applied Sci. 2015;4(11):111-20.
Chatterjee D, Ghosh SK, Sen S, Sarkar S, Hazra A, De R. Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study. Indian J Pharmacol. 2016;48(6):659-64.
Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol Online J. 2016;7(2):77-86.
Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, et al. Expert Consensus on the Management of Dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18(1):6.
Clinard VB, Smith JD. Cutaneous Fungal Infections. US Pharm. 2015;40(4):35-9.
Chatterjee D, Ghosh SK, Sen S, Sarkar S, Hazra A, De R. Efficacy and Tolerability of Topical Sertaconazole versus Topical Terbinafine in Localized Dermatophytosis: A Randomized, Observer-blind, Parallel Group Study. Indian J Pharmacol. 2016;48(6):659-64.
Ogba OM, Abia-Bassey LN. Tinea Cruris Resurgence in Male Genitalia: A Case Report. Int J Basic Applied Innovative Res. 2013;2(3):51-4.
Sheehan DJ, Hitchcock CA, Sibley CM. Current and Emerging Azole Antifungal Agents. Clin Microbiol Rev. 1999;12(1):40-79.
Jerajani HR, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: A pilot study. Indian J Dermatol. 2013;58(1):34-8.
Abdel-Rahman SM, Nahata MC. Oral terbinafine: a new antifungal agent. Ann Pharmacother. 1997;31(4):445-56.
Panagiotidou D, Kousidou T, Chaidemenos G, Karakatsanis G, Kalogeropoulou A, Teknetzis A, et al. A comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris: a double-blind study. J Int Med Res. 1992;20(5):392-400.
Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D Itch Scale: A New Measure of Pruritus. Brit J Dermatol. 2010;162(3):587-93.
Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2009;52(1):95.
Akkus G, Evran M, Gungor D, Karakas M, Sert M, Tetiker T. Tinea pedis and onychomycosis frequency in diabetes mellitus patients and diabetic foot ulcers. A cross sectional-observational study. Pak J Med Sci. 2016;32(4):891-5.
Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Therapeut Clin Risk Management. 2005;1(4):299-306.
Kundu D, Mandal L, Sen G. Prevalence of Tinea capitis in school going children in Kolkata, West Bengal. J Natural Sci Biol Med. 2012;3(2):152-5.
Levin OL, Silvers SH. The isolation of ringworm fungi from sweat. Arch Derm Syphilol. 1931;23(6):1094-9.
Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ. 1999;318(7190):1031-5.
Budimulja U, Kuswadji K, Bramono S, Basuki J, Judanarso LS, Untung S, et al. A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole. Br J Dermatol. 1994;130(43):29-31
Newland JG, Abdel-Rahman SM. Update on terbinafine with a focus on dermatophytoses. Clin Cosmetic Invest Dermatol. 2009;2:49-63.
Itraconazole FDA Label-Capsule. National Institutes of Health, U.S. Department of Health and Human Services. Available at: aidsinfo.nih.gov/drugs/44/itraconazole/59/professional.